Ertugliflozin (Steglatro™) is an orally active sodium glucose co-transporter type 2 inhibitor being developed by Merck and Pfizer as a treatment for type 2 diabetes mellitus (T2DM). Ertugliflozin as monotherapy and in combination with various other antidiabetic drugs was associated with improvements in glycaemic control and secondary outcome measures in the VERTIS phase III clinical trial program. Ertugliflozin and fixed-dose combinations of ertugliflozin and metformin (Segluromet™) and ertugliflozin and sitagliptin (Steglujan™) have recently been approved by the US FDA as an adjunct to diet and exercise to improve glycaemic control in adults with T2DM. These products have also received a positive opinion from the EU Committee for Medicinal Products for Human Use (CHMP). This article summarizes the milestones in the development of ertugliflozin leading to its first approval for T2DM.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process, both Merck and Pfizer were offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. A. Markham is a contracted employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/31B99D70725E4EC0.
- 2.Merck & Co Inc. STEGLATRO™ (ertugliflozin) tablets, for oral use: prescribing information. 2017. http://www.merck.com/. Accessed 9 Feb 2018.
- 3.European Medicines Agency. CHMP summary of opinion: Steglatro (ertugliflozin). 2018. http://www.ema.europa.eu/. Accessed 9 Feb 2018
- 4.Merck & Co Inc. SEGLUROMET™ (ertugliflozin and metformin hydrochloride) tablets, for oral use: prescribing Information. 2017. http://www.accessdata.fda.gov/. Accessed 9 Feb 2018.
- 5.Merck & Co Inc. STEGLUJAN™ (ertugliflozin and sitagliptin) tablets, for oral use: prescribing Information. 2017. http://www.accessdata.fda.gov/. Accessed 9 Feb 2018.
- 6.European Medicines Agency. CHMP summary of opinion: Segluromet (ertugliflozin/metformin). 2018. http://www.ema.europa.eu/. Accessed 9 Feb 2018
- 7.European Medicines Agency. CHMP summary of opinion: Steglujan (ertugliflozin/sitagliptin). 2018.Google Scholar
- 8.Pfizer. FDA approves SGLT2 inhibitor SteglatroTM (ertugliflozin) and fixed-dose combination SteglujanTM (ertugliflozin and sitagliptin) for adults with type 2 diabetes 2017. http://www.pfizer.com/. Accessed 9 Feb 2018
- 10.Sahasrabudhe V, Fediuk DJ, Matschke K, et al. Effect of food on the pharmacokinetics of ertugliflozin and its fixed dose combinations: ertugliflozin/sitagliptin and ertugliflozin/metformin [abstract no. PII-123]. Clin Pharmacol Ther. 2017;101(Suppl 1):S86–7.Google Scholar
- 12.Kumar V, Sahasrabudhe V, Liang Y, et al. Effect of rifampin on the pharmacokinetics of ertugliflozin in healthy subjects [abstract no. PI-063]. Clin Pharmacol Ther. 2016;99(Suppl 1):S47.Google Scholar
- 13.Sahasrabudhe V, Kumar V, Matschke K, et al. Lack of a clinically meaningful pharmacokinetic interaction between ertugliflozin and glimepiride or simvastatin in healthy subjects [abstract no. PI-061]. Clin Pharmacol Ther. 2016;99(Suppl 1):S46–7.Google Scholar
- 14.Kumar V, Liang Y, Wei H, et al. Bioequivalence of ertugliflozin/metformin fixed-dose combination tablets and co-administration of respective strengths of individual components [abstract no. PII-071]. Clin Pharmacol Ther. 2017;101(Suppl. 1):S71.Google Scholar
- 15.Fediuk DJ, Matschke K, Liang Y, et al. Bioequivalence of ertugliflozin/sitagliptin fixed-dose combination tablets and co-administration of respective strengths of individual components. Clin Pharmacol Ther. 2017;101(S1):S63.Google Scholar
- 17.Frias J, Goldman A, Aronson R, et al. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled type 2 diabetes despite diet and exercise: the 52-week VERTIS MONO study [abstract no. 1208-P]. Diabetes. 2017;66:A322–3.Google Scholar
- 21.Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.13116.Google Scholar
- 22.Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.13194.PubMedCentralGoogle Scholar